Below are the most recent publications written about "Administration, Oral" by people in Profiles.
-
Carlo WA, Eichenwald EC, Carper BA, Bell EF, Keszler M, Patel RM, S?nchez PJ, Goldberg RN, D'Angio CT, Van Meurs KP, Hibbs AM, Ambalavanan N, Cosby SS, Newman NS, Vohr BR, Walsh MC, Das A, Ohls RK, Fuller J, Rysavy MA, Ghavam S, Brion LP, Puopolo KM, Moore R, Baack ML, Colaizy TT, Baserga M, Osman AF, Merhar SL, Poindexter BB, DeMauro SB, Kumar V, Cotten CM. Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial. JAMA. 2025 06 24; 333(24):2154-2163.
-
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fern?ndez Land? L, Denning M, Ludwig L, Chen Y. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Sep 18; 393(11):1065-1076.
-
Sutar Y, Adams JS, Wu X, Bhoyarekar V, Garcia Diaz M, Wallace J, Dave M, Zhang QY, Date AA. Rilpivirine Ionic Liquid Nanoemulsion Augments the Oral Bioavailability of Rilpivirine and Its Delivery to the HIV Sanctuary Sites. ACS Appl Mater Interfaces. 2025 Jun 04; 17(22):31954-31970.
-
Daniels MH, Castro J, Lee YT, Gotur D, Knockenhauer KE, Grigoriu S, Lockbaum GJ, Cheong JE, Lu C, Brennan D, Buker SM, Liu J, Yao S, Sparling BA, Sickmier EA, Ribich S, Blakemore SJ, Silver SJ, Boriack-Sjodin PA, Duncan KW, Copeland RA. Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9. J Med Chem. 2025 May 08; 68(9):9537-9554.
-
Adams JS, Sutar Y, Mukkirwar S, Miglani C, Date AA. Sweetening the Deal: Sweetener-Based Ionic Liquid of Albendazole Significantly Enhances Its Solubility and Oral Bioavailability. Mol Pharm. 2025 May 05; 22(5):2568-2580.
-
Albaeni A, Li S, Shan Y, Thakker R, Gaalema DE, Saxena R, Kuo YF, Jneid H, Goodwin J. Outcomes Associated With Novel Oral Anticoagulants and Warfarin in Patients With Cardiac Thrombus Following ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2025 Feb 01; 236:72-78.
-
Pramar YV, Davis C, Ip K, Banov D. Physicochemical and Microbiological Stability of Extemporaneously Compounded Chloral Hydrate Oral Liquid Dosage Forms in PCCA Base, SuspendIt?. Int J Pharm Compd. 2024 Nov-Dec; 28(6):492-501.
-
Gangavarapu A, Tapia-Lopez LV, Sarkar B, Pena-Zacarias J, Badruddoza AZM, Nurunnabi M. Lipid nanoparticles for enhancing oral bioavailability. Nanoscale. 2024 Oct 10; 16(39):18319-18338.
-
Peng X, Guo S, Zheng S, Hossain A, Zhang C, Mottamal M, Skripnikova E, Ma P, Martinez-Carter K, Zhang Q, Abedin F, Huckaba T, Wang G. Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations. J Med Chem. 2024 Oct 24; 67(20):18098-18123.
-
Garg M, Venugopalan V, Vouri SM, Diaby V, Iovine NM, Wilson DL, Park H. Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018. Pharmacotherapy. 2024 Sep; 44(9):701-710.